Clin Respir J. 2021 Aug 16. doi: 10.1111/crj.13438. Online ahead of print.
ABSTRACT
The SARS-CoV-2 is a new coronavirus responsible for the COVID-19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID-19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID-19 patients such as inflammation, endothelitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE and, CINAHL from January 2020 to December 2020. We used the following search terms; COVID-19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID-19 associated coagulopathy.
PMID:34399021 | DOI:10.1111/crj.13438